Cost-Effectiveness of Celecoxib for Osteoarthritis
Author Information
Author(s): Michael Loyd, Dale Rublee, Philip Jacobs
Primary Institution: Michael Loyd & Associates Ltd, Winnipeg, Manitoba, Canada
Hypothesis
Is celecoxib more cost-effective than nonselective NSAIDs for treating osteoarthritis in 60-year-old patients?
Conclusion
Chronic use of celecoxib is cost-effective compared to nonselective NSAIDs for 60-year-old osteoarthritis patients with average gastrointestinal risks.
Supporting Evidence
- The incremental cost-effectiveness ratio for celecoxib was $31,097 per QALY.
- Age-related increases in gastrointestinal risks lowered the ICER to $19,309.
- Including serious cardiovascular risks reduced the ICER to $17,120.
Takeaway
This study shows that taking celecoxib instead of regular painkillers can save money in the long run for older people with arthritis.
Methodology
Decision analysis based on literature data to evaluate cost-effectiveness over patients' lifetimes.
Potential Biases
Potential biases in the selection of clinical trial data and assumptions about long-term outcomes.
Limitations
The model's results may not be generalizable to all osteoarthritis populations and are based on specific assumptions about drug prices and risks.
Participant Demographics
60-year-old patients with osteoarthritis requiring chronic NSAID therapy.
Statistical Information
Confidence Interval
95% CI for dyspepsia rates: nsNSAIDs 12.0% (9.9%–14.0%), celecoxib 7.8% (6.0%–9.5%)
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website